Dec 9, 2024, 13:18
Pembrolizumab vs chemotherapy in MSI-high or MMR-deficient metastatic colorectal cancer
Shivani Modi shared a post on X:
“Talk of the town!
KEYNOTE-177 trial shows
- mFU: 73.3 months.
- Crossover 62 percent
- 5 year Overall Survival 55 percent vs 44 percent
- median Overall Survival 77.5 vs 36.7 months
- (2 year Progression-free survival 48.3 percent — CM-8HW72 percent )
- Pembrolizumab ? Nivo+İpi?
Authors: K.-K. Shiu, T.W. Kim, B.V. Jensen, L.H. Jensen, C.J.A. Punt, D. Smith, R. Garcia-Carbonero, J. Alcaide-Garcia, P. Gibbs, C. de la Fouchardiere, F. Rivera, E. Elez, D.T. Le, T. Yoshino, Y. Zuo, D. Fogelman, D. Adelberg, ”
Shivani Modi is a Resident Physician at Jefferson Health, with an interest in pursuing a career in Hematology/Oncology. Previously, she served as a professor at a Mexican medical school and was a research mentor at IMG Helping Hands.
B.V. Jensen
C. de la Fouchardière
C.J.A. Punt
cancer
chemotherapy
D. Adelberg
D. Fogelman
D. Smith
D.T. Le
E. Elez
F. Rivera
J. Alcaide-Garcia
K.-K. Shiu
L.A. Diaz
L.H. Jensen
median overall survival
Metastatic colorectal cancer
mFU
MSI-High
OncoDaily
Oncology
Overall survival (OS)
P. Gibbs
pembrolizumab
progression-free survival
R. Garcia-Carbonero
Shivani Modi
T. André
T. Yoshino
T.W. Kim
Y. Zuo
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 10, 2025, 20:10
Jan 10, 2025, 19:51
Jan 10, 2025, 19:16
Jan 10, 2025, 18:33
Jan 10, 2025, 18:28